Welcome to NewPressRelease.com a free press release service. Publishing press releases for Public Relations never been easier. Just register (it's free and it takes less then a 1 minute) then use Submit Press Release. Our services aim to help you reach journalists and to improve visibility in search engine listings, so you can get the most publicity possible.

RAPS pre-approved webinar on The Investigational Medicinal Product Dossier (IMPD): EU CTA vs. FDA I

Events & Concerts

(Free Press Release) “The Investigational Medicinal Product Dossier (IMPD): EU CTA vs. FDA IND” is the topic of a RAPS pre-approved webinar that GlobalCompliancePanel, a leading regulatory and compliance continuing education training provider, will organize on June 4. Robert J. Russell, President of RJR Consulting, Inc. will be the Speaker at this 90-minute webinar, which earns up to 1.5 RAC credits towards a participant's RAC recertification upon full completion.

RAPS pre-approved webinar on The Investigational Medicinal Product Dossier (IMPD): EU CTA vs. FDA I




This webinar gives a comprehensive understanding of the IMPD (Investigational Medicinal Product Dossier) and the structure and content differences between an EU CTA Application and an FDA IND Application.

Having the knowledge and efficiency in completing successful applications for their studies is of utmost importance to sponsors, CROs, Sites and auditors of Clinical Research who are involved in pharmaceutical or biological development. This is because knowing what is expected and getting it right the first time will allow faster development of innovative products. The result of all this is personal and company success, which in turn paves the way for the availability of new therapies to patient populations worldwide.

This webinar will also cover many related processes sponsors will need to know, as they file for, conduct and close out effective clinical studies in the U.S. and EU.

o US FDA and EU Agency Orientation/Structure

o Start-up and conducting clinical trial processes

o Following Product Registration/Licensing Options

o Company Strategy –Linking Clinical Trials & Marketing Authorization Applications

o Balancing strategy and long term regulatory cost & maintenance

o IMP dossier & comparisons of the US IND to the EU CTA content

o Scientific Advice: Member States vs. Pre-IND meetings with U.S. FDA

o Orphan drugs: EU vs. US treatment

o GCP Compliance Inspections

o Essentially similar and generic products

o Cross-agency interactions: comparing U.S. FDA and EMA

o Effective interactions with the global regulatory healthcare authorities

o Helpful websites


When:June 4, 10:00 AM PDT | 01:00 PM EDT


By whom:Robert J. Russell is President of RJR Consulting, Inc. The company assists the pharmaceutical, medical device and biotech industries in understanding and complying with International Regulations affecting compliance, new product development, manufacturing and quality assurance. RJR has offices in Columbus, OH, Washington DC, and Brussels, Belgium with exclusive affiliates across Asia and Latin America.

Bob has 28 years of past industry experience as a CMC specialist, R&D Director and Global Director of Regulatory Affairs for Merion Merrill Dow pharmaceuticals and Cordis-Dow medical devices. He has a BS/MS degree in Chemistry.


For whom:

The webinar will benefit

o Sponsor Senior management

o Project Managers

o Clinical Trial Heads

o Medical writers

o Project Managers

o CRAs and CRCs

o QA/Compliance personnel

o Investigators

o Clinical Research Scientists

o QA/QC Auditors and Staff

o Consultants


Duration: 90 minutes


To enroll for this webinar, contact

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Phone: 800-447-9407


RAPS pre-approved webinar on The Investigational Medicinal Product Dossier (IMPD): EU CTA vs. FDA I

Source: Press Release



If you have any questions regarding information in this press release, please contact the person listed as the Author or use the contact informations published in the press release. Please do not attempt to contact NewPressRelease.com. We are unable to assist you with any information regarding this release. NewPressRelease.com disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.

All press release information on this site, including free press releases, is solely based on what our users submit. NewPressRelease.com disclaims that any right and responsibility for the information goes to the user who submit the press release. Some press release may be confusing without additional explanation. You should contact the provider with any questions about the information presented. In case some press release damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.

Copyright © 2008 - 2018 Free Press Release by NewPressRelease.com